{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:57:24Z","timestamp":1785527844173,"version":"3.56.0"},"reference-count":172,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05735-6","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T01:39:03Z","timestamp":1785202743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipid-based nanocarrier-enabled combination therapy for breast cancer: overcoming drug resistance toward precision oncology"],"prefix":"10.1007","author":[{"given":"Abdul","family":"Shadab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Faheem","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abohassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"5735_CR1","doi-asserted-by":"publisher","unstructured":"Agostinelli V, Torresi G, Tarantino V, Goteri G, Filosa A, Barbisan F, Bartoli E, Bianchi F, Chiodi N, Ambrosini E, Ricci G, Lucarelli A, Burattini M, Biagioni A, Chiariotti S, Magi S, Mentrasti G, Morgese F, Papa R, \u2026 Berardi R (2025) The impact and performance of the molecular tumor board: three-year activity in precision medicine for treatment of patients with cancer from the Marche Region, in Italy. Oncol Ther 13:201\u2013215. https:\/\/doi.org\/10.1007\/s40487-025-00325-7","DOI":"10.1007\/s40487-025-00325-7"},{"key":"5735_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030480","volume":"16","author":"P Ahluwalia","year":"2024","unstructured":"Ahluwalia P, Ballur K, Leeman T, Vashisht A, Singh H, Omar N, Mondal A, Vaibhav K, Baban B, Kolhe R (2024) Incorporating novel technologies in precision oncology for colorectal cancer: advancing personalized medicine. Cancers 16. https:\/\/doi.org\/10.3390\/cancers16030480","journal-title":"Cancers"},{"key":"5735_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.08.011","author":"D Akhoundova","year":"2022","unstructured":"Akhoundova D, Rubin M (2022) Clinical application of advanced multi-omics tumor profiling: shaping precision oncology of the future. Cancer Cell. https:\/\/doi.org\/10.1016\/j.ccell.2022.08.011","journal-title":"Cancer Cell"},{"key":"5735_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17435889.2025.2523730","volume":"1\u201324","author":"M Alawi","year":"2025","unstructured":"Alawi M, Hilles A, Kumar M, Ansari MD, Mahmood S (2025) Lipid-polymer hybrid nanoparticles: a cutting-edge frontier in breast cancer treatment strategies. Nanomedicine 1\u201324:1. https:\/\/doi.org\/10.1080\/17435889.2025.2523730","journal-title":"Nanomedicine"},{"issue":"4","key":"5735_CR5","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1158\/2159-8290.cd-20-1638","volume":"11","author":"M Aldea","year":"2021","unstructured":"Aldea M, Andr\u00e9 F, Marabelle A, Dogan S, Barlesi F, Soria J (2021) Overcoming resistance to tumor-targeted and immune-targeted therapies. Cancer Discov 11(4):874\u2013899. https:\/\/doi.org\/10.1158\/2159-8290.cd-20-1638","journal-title":"Cancer Discov"},{"key":"5735_CR6","doi-asserted-by":"publisher","unstructured":"Aleixo DT, Cruz-Cazarim E, Ferreira K, Grossi L, Braz W, Silva N, Pittella-Silva F, Dias M, Fialho S, Tavares G, Pittella F (2025) Breakthroughs in the nanoparticle-mediated delivery of siRNA for breast cancer treatment. Nanomedicine 1\u201325. https:\/\/doi.org\/10.1080\/17435889.2025.2567842","DOI":"10.1080\/17435889.2025.2567842"},{"key":"5735_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/biom15040535","author":"S Alqahtani","year":"2025","unstructured":"Alqahtani S, Alqahtani T, Venkatesan K, Sivadasan D, Ahmed R, Elfadil H, Paulsamy P, Periannan K (2025) Unveiling pharmacogenomics insights into circular RNAs: toward precision medicine in cancer therapy. Biomolecules. https:\/\/doi.org\/10.3390\/biom15040535","journal-title":"Biomolecules"},{"key":"5735_CR8","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2022","unstructured":"Anand U, Dey A, Chandel AS, Sanyal R, Mishra A, Pandey D, de Falco V, Upadhyay AP, Kandimalla R, Chaudhary A, Dhanjal J, Dewanjee S, Vallamkondu J, de La Lastra JP (2022) Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis 10:1367\u20131401. https:\/\/doi.org\/10.1016\/j.gendis.2022.02.007","journal-title":"Genes Dis"},{"key":"5735_CR9","doi-asserted-by":"publisher","DOI":"10.3892\/br.2025.1921","author":"A Aravantinou-fatorou","year":"2025","unstructured":"Aravantinou-fatorou A, Georgakopoulou V, Dimopoulos M, Liontos M (2025) Precision medicine in gynecological cancer (review). Biomed Rep. https:\/\/doi.org\/10.3892\/br.2025.1921","journal-title":"Biomed Rep"},{"key":"5735_CR10","doi-asserted-by":"publisher","unstructured":"Ashrafi A, Akter Z, Modareszadeh P, Modareszadeh P, Berisha E, Alemi PS, del Carmen Chacon Castro M, Deese A, Zhang L (2022) Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance. Cancers 14. https:\/\/doi.org\/10.3390\/cancers14194562","DOI":"10.3390\/cancers14194562"},{"key":"5735_CR11","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/med.21971","volume":"43","author":"M Ashrafizadeh","year":"2023","unstructured":"Ashrafizadeh M, Zarrabi A, Bigham A, Taheriazam A, Saghari Y, Mirzaei S, Hashemi M, Hushmandi K, Karimi-Maleh H, Zare EN, Sharifi E, Ertas Y, Rabiee N, Sethi G, Shen M (2023) (Nano)platforms in breast cancer therapy: drug\/gene delivery, advanced nanocarriers and immunotherapy. Med Res Rev 43:2115\u20132176. https:\/\/doi.org\/10.1002\/med.21971","journal-title":"Med Res Rev"},{"key":"5735_CR12","doi-asserted-by":"publisher","unstructured":"Attar M, Tash Shamsabadi F, Soltani A, Joghataei MT, Khandoozi SR, Teimourian S, Shahbazi M, Erfani-Moghadam V (2025) MF59-based lipid nanocarriers for paclitaxel delivery: optimization and anticancer evaluation. Sci Rep 15(1), 6583. https:\/\/doi.org\/10.1038\/s41598-025-91504-z","DOI":"10.1038\/s41598-025-91504-z"},{"key":"5735_CR13","doi-asserted-by":"publisher","unstructured":"Awada\u00a0 A, Bondarenko IN, Bonneterre J, Nowara E, Ferrero JM, Bakshi AV, Wilke C, Piccart M, CT4002 study group (2014). A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Annals of oncology : official journal of the European Society for Medical Oncology, 25(4), 824\u2013831. https:\/\/doi.org\/10.1093\/annonc\/mdu025","DOI":"10.1093\/annonc\/mdu025"},{"key":"5735_CR14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.20892\/j.issn.2095-3941.2024.0510","volume":"22","author":"J Bai","year":"2025","unstructured":"Bai J, Gao Y, Zhang G (2025) The treatment of breast cancer in the era of precision medicine. Cancer Biol Med 22:322\u2013347. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2024.0510","journal-title":"Cancer Biol Med"},{"issue":"2","key":"5735_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y (2012) Doxil\u00ae\u2013the first FDA-approved nano-drug: lessons learned. Journal of controlled release\u202f: official journal of the Controlled Release Society 160(2):117\u2013134. https:\/\/doi.org\/10.1016\/j.jconrel.2012.03.020","journal-title":"Journal of controlled release : official journal of the Controlled Release Society"},{"issue":"3","key":"5735_CR16","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/annonc\/mdt543","volume":"25","author":"J Baselga","year":"2014","unstructured":"Baselga J, Manikhas A, Cort\u00e9s J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M (2014) Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Annals of oncology\u202f: official journal of the European Society for Medical Oncology 25(3):592\u2013598. https:\/\/doi.org\/10.1093\/annonc\/mdt543","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"issue":"5","key":"5735_CR17","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","volume":"19","author":"G Batist","year":"2001","unstructured":"Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. Journal of clinical oncology\u202f: official journal of the American Society of Clinical Oncology 19(5):1444\u20131454. https:\/\/doi.org\/10.1200\/JCO.2001.19.5.1444","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"5735_CR18","doi-asserted-by":"publisher","unstructured":"Borys N, Dewhirst MW (2021) Drug development of lyso-thermosensitive liposomal doxorubicin: combining hyperthermia and thermosensitive drug delivery. Adv Drug Deliv Rev 178, 113985. https:\/\/doi.org\/10.1016\/j.addr.2021.113985","DOI":"10.1016\/j.addr.2021.113985"},{"key":"5735_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17213500","author":"P Brlek","year":"2025","unstructured":"Brlek P, \u0160karo V, Hrvatin N, Buli\u0107 L, Petrovi\u0107 A, Proji\u0107 P, Smoli\u0107 M, Shah P, Primorac D (2025) Advances in precision oncology: from molecular profiling to regulatory-approved targeted therapies. Cancers. https:\/\/doi.org\/10.3390\/cancers17213500","journal-title":"Cancers"},{"key":"5735_CR20","doi-asserted-by":"publisher","unstructured":"Bukhari S (2022) Emerging nanotherapeutic approaches to overcome drug resistance in cancers with update on clinical trials. Pharmaceutics 14. https:\/\/doi.org\/10.3390\/pharmaceutics14040866","DOI":"10.3390\/pharmaceutics14040866"},{"key":"5735_CR21","doi-asserted-by":"publisher","unstructured":"Cao L, Zhu YQ, Wang W, Wang G, Zhang S, Cheng H (2021) Emerging nano-based strategies against drug resistance in tumor chemotherapy. Front Bioeng Biotechnol 9. https:\/\/doi.org\/10.3389\/fbioe.2021.798882","DOI":"10.3389\/fbioe.2021.798882"},{"key":"5735_CR22","doi-asserted-by":"publisher","unstructured":"Carnevale M, Colciago R, de Santis M, Cortesi L, de Marco C, Marra A, Vingiani A, Nol\u00e8 F, Curigliano G, Pruneri G, Llombart-Cussac A, di Cosimo S, Cort\u00e9s J (2025) Advancing breast cancer therapy in the era of molecular diagnostics. The Breast 82. https:\/\/doi.org\/10.1016\/j.breast.2025.104488","DOI":"10.1016\/j.breast.2025.104488"},{"key":"5735_CR23","doi-asserted-by":"publisher","unstructured":"Catalano A, Iacopetta D, Ceramella J, Scumaci D, Giuzio F, Saturnino C, Aquaro S, Rosano C, Sinicropi M (2022) Multidrug resistance (MDR): a widespread phenomenon in pharmacological therapies. Molecules 27. https:\/\/doi.org\/10.3390\/molecules27030616","DOI":"10.3390\/molecules27030616"},{"key":"5735_CR24","doi-asserted-by":"publisher","unstructured":"Chavda V, Nalla LV, Balar P, Bezbaruah R, Apostolopoulos V, Singla R, Khadela A, Vora L, Uversky V (2023) Advanced phytochemical-based nanocarrier systems for the treatment of breast cancer. Cancers 15. https:\/\/doi.org\/10.3390\/cancers15041023","DOI":"10.3390\/cancers15041023"},{"key":"5735_CR25","doi-asserted-by":"publisher","unstructured":"Chen D, Liu X, Lu X, Tian J (2023) Nanoparticle drug delivery systems for synergistic delivery of tumor therapy. Front Pharmacol 14. https:\/\/doi.org\/10.3389\/fphar.2023.1111991","DOI":"10.3389\/fphar.2023.1111991"},{"key":"5735_CR26","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.2147\/ijn.s388066","volume":"17","author":"W-J Cheng","year":"2022","unstructured":"Cheng W-J, Lin S, Chuang K-H, Chen M, Ho H, Chen L-C, Hsieh C, Sheu M (2022) Combined docetaxel\/pictilisib-loaded mPEGylated nanocarriers with dual HER2 targeting antibodies for synergistic chemotherapy of breast cancer. Int J Nanomedicine 17:5353\u20135374. https:\/\/doi.org\/10.2147\/ijn.s388066","journal-title":"Int J Nanomedicine"},{"key":"5735_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15112610","author":"A Cunha","year":"2023","unstructured":"Cunha A, Silva P, Sarmento B, Queir\u00f3s O (2023) Targeting glucose metabolism in cancer cells as an approach to overcoming drug resistance. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15112610","journal-title":"Pharmaceutics"},{"key":"5735_CR28","doi-asserted-by":"publisher","unstructured":"Dakilah I, Harb A, Abu-Gharbieh E, El\u2010Huneidi W, Taneera J, Hamoudi R, Semreen M, Bustanji Y (2024) Potential of CDC25 phosphatases in cancer research and treatment: key to precision medicine. Front Pharmacol 15. https:\/\/doi.org\/10.3389\/fphar.2024.1324001","DOI":"10.3389\/fphar.2024.1324001"},{"key":"5735_CR29","doi-asserted-by":"publisher","unstructured":"Davis L, Sherbenou D (2021) Emerging therapeutic strategies to overcome drug resistance in multiple myeloma. Cancers 13. https:\/\/doi.org\/10.3390\/cancers13071686","DOI":"10.3390\/cancers13071686"},{"key":"5735_CR30","doi-asserted-by":"publisher","unstructured":"Dechbumroong P, Hu R, Keaswejjareansuk W, Namdee K, Liang XJ (2024) Recent advanced lipid-based nanomedicines for overcoming cancer resistance. Cancer Drug Resist 7. https:\/\/doi.org\/10.20517\/cdr.2024.19","DOI":"10.20517\/cdr.2024.19"},{"key":"5735_CR31","doi-asserted-by":"publisher","DOI":"10.2174\/0115680096333058241114064802","author":"R Deshmukh","year":"2025","unstructured":"Deshmukh R, Verma S, Yaduwanshi P, Dubey A, Kumari M (2025) Molecular-targeted therapy for precision medicine in gastrointestinal cancer: advancement in cancer targeting strategies. Curr Cancer Drug Targets. https:\/\/doi.org\/10.2174\/0115680096333058241114064802","journal-title":"Curr Cancer Drug Targets"},{"key":"5735_CR32","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1080\/09205063.2025.2510441","volume":"36","author":"H Dewangan","year":"2025","unstructured":"Dewangan H, Sharma R, Marwah H, Shah K, Alam P (2025) Nanostructured solid lipid for paclitaxel and kaempferol co-delivery as a novel synergistic approach for breast cancer. J Biomater Sci Polym Ed 36:2837\u20132858. https:\/\/doi.org\/10.1080\/09205063.2025.2510441","journal-title":"J Biomater Sci Polym Ed"},{"key":"5735_CR33","doi-asserted-by":"publisher","unstructured":"Dhiman R, Bazad N, Mukherjee R, Himanshu, Gunjan, Leal E, Ahmad S, Kaur K, Raj V, Chang CM, Pandey R (2024) Enhanced drug delivery with nanocarriers: a comprehensive review of recent advances in breast cancer detection and treatment. Discover Nano 19. https:\/\/doi.org\/10.1186\/s11671-024-04086-6","DOI":"10.1186\/s11671-024-04086-6"},{"key":"5735_CR34","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2147\/ijn.s289443","volume":"16","author":"Z Edis","year":"2021","unstructured":"Edis Z, Wang J, Waqas M, Ijaz M, Ijaz M (2021) Nanocarriers-mediated drug delivery systems for anticancer agents: an overview and perspectives. Int J Nanomedicine 16:1313\u20131330. https:\/\/doi.org\/10.2147\/ijn.s289443","journal-title":"Int J Nanomedicine"},{"key":"5735_CR35","doi-asserted-by":"publisher","unstructured":"El-Deiry W, Bresson C, Wunder F, Carneiro B, Dizon D, Warner J, Graff S, Azzoli C, Wong E, Cheng L, Mani S, Safran H, Williams C, Meissner T, Solomon B, Rubin E, Porgador A, Berchem G, Saintigny P, \u2026, Kurzrock R (2025) Worldwide innovative network (WIN) consortium in personalized cancer medicine: bringing next-generation precision oncology to patients. Oncotarget 16:140\u2013162. https:\/\/doi.org\/10.18632\/oncotarget.28703","DOI":"10.18632\/oncotarget.28703"},{"key":"5735_CR36","doi-asserted-by":"publisher","unstructured":"Emran T, Shahriar A, Mahmud AR, Rahman T, Abir MH, Siddiquee Mohd FR, Ahmed H, Rahman N, Nainu F, Wahyudin E, Mitra S, Dhama K, Habiballah M, Haque S, Islam A, Hassan M (2022) Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front Oncol 12. https:\/\/doi.org\/10.3389\/fonc.2022.891652","DOI":"10.3389\/fonc.2022.891652"},{"key":"5735_CR37","doi-asserted-by":"publisher","unstructured":"Eslami M, Memarsadeghi O, Davarpanah A, Arti A, Nayernia K, Behnam B (2024) Overcoming chemotherapy resistance in metastatic cancer: a comprehensive review. Biomedicines 12. https:\/\/doi.org\/10.3390\/biomedicines12010183","DOI":"10.3390\/biomedicines12010183"},{"key":"5735_CR38","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.3390\/curroncol30020191","volume":"30","author":"R Falcone","year":"2023","unstructured":"Falcone R, Lombardi P, Filetti M, Fabi A, Altamura V, Scambia G, Daniele G (2023) Molecular profile and matched targeted therapy for advanced breast cancer patients. Curr Oncol 30:2501\u20132509. https:\/\/doi.org\/10.3390\/curroncol30020191","journal-title":"Curr Oncol"},{"key":"5735_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100054","author":"P Famta","year":"2021","unstructured":"Famta P, Shah S, Chatterjee E, Singh H, Dey B, Guru S, Singh S, Srivastava S (2021) Exploring new horizons in overcoming P-glycoprotein-mediated multidrug-resistant breast cancer via nanoscale drug delivery platforms. Curr Res Pharmacol Drug Discov. https:\/\/doi.org\/10.1016\/j.crphar.2021.100054","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"5735_CR40","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/17460441.2022.2112666","volume":"17","author":"M Feyzizadeh","year":"2022","unstructured":"Feyzizadeh M, Barfar A, Nouri Z, Sarfraz M, Zakeri-Milani P, Valizadeh H (2022) Overcoming multidrug resistance through targeting ABC transporters: lessons for drug discovery. Expert Opin Drug Discov 17:1013\u20131027. https:\/\/doi.org\/10.1080\/17460441.2022.2112666","journal-title":"Expert Opin Drug Discov"},{"key":"5735_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01102-1","author":"E Fountzilas","year":"2022","unstructured":"Fountzilas E, Tsimberidou A, Vo H, Kurzrock R (2022) Clinical trial design in the era of precision medicine. Genome Med. https:\/\/doi.org\/10.1186\/s13073-022-01102-1","journal-title":"Genome Med"},{"key":"5735_CR42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","volume":"29","author":"AA Gabizon","year":"2016","unstructured":"Gabizon AA, Patil Y, La-Beck NM (2016) New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug resistance updates\u202f: reviews and commentaries in antimicrobial and anticancer chemotherapy 29:90\u2013106. https:\/\/doi.org\/10.1016\/j.drup.2016.10.003","journal-title":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"5735_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/biom15060802","volume":"15","author":"R Ganpisetti","year":"2025","unstructured":"Ganpisetti R, Giridharan S, Sainaga G, Vaskuri J, Narang N, Basim P, Dokmeci M, Ermis M, Rojekar S, Gholap A, Kommineni N (2025) Biological nanocarriers in cancer therapy: cutting edge innovations in precision drug delivery. Biomolecules 15. https:\/\/doi.org\/10.3390\/biom15060802","journal-title":"Biomolecules"},{"key":"5735_CR44","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1016\/j.apsb.2024.03.012","volume":"14","author":"F Gao","year":"2024","unstructured":"Gao F, Wu Y, Wang R, Yao Y, Liu Y, Fan L, Xu J, Zhang J, Han X, Guan X (2024) Precise nano-system-based drug delivery and synergistic therapy against androgen receptor-positive triple-negative breast cancer. Acta Pharm Sin B 14:2685\u20132697. https:\/\/doi.org\/10.1016\/j.apsb.2024.03.012","journal-title":"Acta Pharm Sin B"},{"key":"5735_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132478","author":"P Garg","year":"2024","unstructured":"Garg P, Malhotra J, Kulkarni P, Horne D, Salgia R, Singhal S (2024) Emerging therapeutic strategies to overcome drug resistance in cancer cells. Cancers. https:\/\/doi.org\/10.3390\/cancers16132478","journal-title":"Cancers"},{"key":"5735_CR46","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.6c00618","author":"L Gillman","year":"2026","unstructured":"Gillman L, Suleski D, Graham ME, Ginn SL, Hassan MdM (2026) Pharmaceutical Engineering of Lipid-Based Nanocarriers for Cancer Nanomedicines: From Doxorubicin to mRNA Platforms. ACS Biomaterials Science & Engineering. https:\/\/doi.org\/10.1021\/acsbiomaterials.6c00618","journal-title":"ACS Biomaterials Science & Engineering"},{"key":"5735_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16091158","author":"A Giordano","year":"2024","unstructured":"Giordano A, Provenza AC, Reverchon G, Baldino L, Reverchon E (2024) Lipid-based nanocarriers: bridging diagnosis and cancer therapy. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics16091158","journal-title":"Pharmaceutics"},{"key":"5735_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094673","author":"V Gote","year":"2021","unstructured":"Gote V, Nookala A, Bolla PK, Pal D (2021) Drug resistance in metastatic breast cancer: tumor targeted nanomedicine to the rescue. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22094673","journal-title":"Int J Mol Sci"},{"key":"5735_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031257","volume":"22","author":"V Gote","year":"2021","unstructured":"Gote V, Sharma AD, Pal D (2021) Hyaluronic acid-targeted stimuli-sensitive nanomicelles co-encapsulating paclitaxel and ritonavir to overcome multi-drug resistance in metastatic breast cancer and triple-negative breast cancer cells. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/ijms22031257","journal-title":"Int J Mol Sci"},{"key":"5735_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.cis.2023.102871","volume":"314","author":"P Grav\u00e1n","year":"2023","unstructured":"Grav\u00e1n P, Aguilera-Garrido A, Marchal J, Navarro-Marchal S, Galisteo-Gonz\u00e1lez F (2023) Lipid-core nanoparticles: classification, preparation methods, routes of administration and recent advances in cancer treatment. Adv Colloid Interface Sci 314. https:\/\/doi.org\/10.1016\/j.cis.2023.102871","journal-title":"Adv Colloid Interface Sci"},{"key":"5735_CR51","doi-asserted-by":"publisher","unstructured":"Gu Y, Yang R, Zhang Y, Guo M, Takehiro K, Zhan M, Yang L, Wang H (2025) Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer. Mol Biomed 6. https:\/\/doi.org\/10.1186\/s43556-024-00239-2","DOI":"10.1186\/s43556-024-00239-2"},{"key":"5735_CR52","doi-asserted-by":"publisher","unstructured":"Guo M, Sun Y, Wei Y, Xu J, Zhang C (2024) Advances in targeted therapy and biomarker research in thyroid cancer. Front Endocrinol 15. https:\/\/doi.org\/10.3389\/fendo.2024.1372553","DOI":"10.3389\/fendo.2024.1372553"},{"key":"5735_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbiomolbio.2025.02.003","author":"T Gupta","year":"2025","unstructured":"Gupta T, Murtaza M (2025) Advancing targeted therapies in pancreatic cancer: leveraging molecular aberrations for therapeutic success. Prog Biophys Mol Biol. https:\/\/doi.org\/10.1016\/j.pbiomolbio.2025.02.003","journal-title":"Prog Biophys Mol Biol"},{"key":"5735_CR54","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1007\/s13346-023-01366-z","volume":"13","author":"P Gupta","year":"2023","unstructured":"Gupta P, Neupane Y, Aqil M, Kohli K, Sultana Y (2023) Lipid-based nanoparticle-mediated combination therapy for breast cancer management: a comprehensive review. Drug Deliv Transl Res 13:2739\u20132766. https:\/\/doi.org\/10.1007\/s13346-023-01366-z","journal-title":"Drug Deliv Transl Res"},{"key":"5735_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26051988","author":"J Haynes","year":"2025","unstructured":"Haynes J, Manogaran P (2025) Mechanisms and strategies to overcome drug resistance in colorectal cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26051988","journal-title":"Int J Mol Sci"},{"key":"5735_CR56","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1007\/s10147-025-02755-9","volume":"30","author":"T Hida","year":"2025","unstructured":"Hida T (2025) Genomic profiling and personalized treatment strategies for skin malignancies: findings from the center for cancer genomics and advanced therapeutics database. Int J Clin Oncol 30:856\u2013866. https:\/\/doi.org\/10.1007\/s10147-025-02755-9","journal-title":"Int J Clin Oncol"},{"key":"5735_CR57","doi-asserted-by":"publisher","unstructured":"Hristova-Panusheva K, Xenodochidis C, Georgieva M, Krasteva N (2024) Nanoparticle-mediated drug delivery systems for precision targeting in oncology. Pharmaceuticals 17. https:\/\/doi.org\/10.3390\/ph17060677","DOI":"10.3390\/ph17060677"},{"key":"5735_CR58","doi-asserted-by":"publisher","unstructured":"Hu T, Gong H, Xu J, Huang Y, Wu F, He Z (2022) Nanomedicines for overcoming cancer drug resistance. Pharmaceutics 14. https:\/\/doi.org\/10.3390\/pharmaceutics14081606","DOI":"10.3390\/pharmaceutics14081606"},{"key":"5735_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01137-8","volume":"14","author":"H Hua","year":"2021","unstructured":"Hua H, Zhang H, Chen J, Wang J, Liu J, Jiang Y (2021) Targeting Akt in cancer for precision therapy. J Hematol Oncology 14. https:\/\/doi.org\/10.1186\/s13045-021-01137-8","journal-title":"J Hematol Oncology"},{"key":"5735_CR60","doi-asserted-by":"publisher","first-page":"6133","DOI":"10.2147\/ijn.s488545","volume":"20","author":"Z Izadiyan","year":"2025","unstructured":"Izadiyan Z, Webster T, Kia P, Kalantari K, Misran M, Rasouli E, Esfahan ZM, Shameli K (2025) Nanoemulsions based therapeutic strategies: enhancing targeted drug delivery against breast cancer cells. Int J Nanomedicine 20:6133\u20136162. https:\/\/doi.org\/10.2147\/ijn.s488545","journal-title":"Int J Nanomedicine"},{"key":"5735_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17060779","author":"A Jadhav","year":"2025","unstructured":"Jadhav A, Nagaraj K (2025) Surfactant-enabled nanocarriers in breast cancer therapy: targeted delivery and multidrug resistance reversal. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics17060779","journal-title":"Pharmaceutics"},{"key":"5735_CR62","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1080\/09205063.2024.2303196","volume":"35","author":"S Jamali","year":"2024","unstructured":"Jamali S, Jamali B, Abedi F, Firoozrai M, Davaran S, Moghaddam SV (2024) Folate receptor-mediated delivery system based on chitosan coated polymeric nanoparticles for combination therapy of breast cancer. J Biomater Sci Polym Ed 35:605\u2013627. https:\/\/doi.org\/10.1080\/09205063.2024.2303196","journal-title":"J Biomater Sci Polym Ed"},{"key":"5735_CR63","doi-asserted-by":"publisher","unstructured":"Kasprzak J, Westphalen C, Frey S, Schmitt Y, Heinemann V, Fey T, Nasseh D (2024) Supporting the decision to perform molecular profiling for cancer patients based on routinely collected data through the use of machine learning. Clin Exp Med 24. https:\/\/doi.org\/10.1007\/s10238-024-01336-w","DOI":"10.1007\/s10238-024-01336-w"},{"key":"5735_CR64","doi-asserted-by":"publisher","unstructured":"Kaushik N, Borkar S, Nandanwar S, Panda P, Choi E, Kaushik N (2022) Nanocarrier cancer therapeutics with functional stimuli-responsive mechanisms. J Nanobiotechnol 20. https:\/\/doi.org\/10.1186\/s12951-022-01364-2","DOI":"10.1186\/s12951-022-01364-2"},{"key":"5735_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-67934-6","volume":"14","author":"F Kazeminava","year":"2024","unstructured":"Kazeminava F, Javanbakht S, Latifi Z, Rasoulzadehzali M, Abbaszadeh M, Alimohammadzadeh B, Mahdipour M, Fattahi A, Hamishehkar H, Adibag Z, Nouri M (2024) Ultrasound-assisted encapsulating folic acid-based carbon quantum dots within breast cancer cell-derived exosomes as a co-receptors-mediated anticancer nanocarrier for enhanced breast cancer therapy. Scientific Reports 14. https:\/\/doi.org\/10.1038\/s41598-024-67934-6","journal-title":"Scientific Reports"},{"key":"5735_CR66","doi-asserted-by":"publisher","first-page":"248","DOI":"10.34172\/apb.025.45109","volume":"15","author":"M Keerikkadu","year":"2025","unstructured":"Keerikkadu M, Bangera PD, Tippavajhala VK, Rathnanand M (2025) An overview on lipid nanocapsules: exploring the role in precision cancer treatment and lymphatic drug distribution. Adv Pharm Bull 15:248\u2013267. https:\/\/doi.org\/10.34172\/apb.025.45109","journal-title":"Adv Pharm Bull"},{"key":"5735_CR67","doi-asserted-by":"publisher","unstructured":"Khoury R, Raffoul C, Khater C, Hanna C (2025) Precision medicine in hematologic malignancies: evolving concepts and clinical applications. Biomedicines 13. https:\/\/doi.org\/10.3390\/biomedicines13071654","DOI":"10.3390\/biomedicines13071654"},{"key":"5735_CR68","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10585-024-10291-5","volume":"41","author":"K Kim","year":"2024","unstructured":"Kim K (2024) Personalized therapy in oncology: melanoma as a paradigm for molecular-targeted treatment approaches. Clin Exp Metastasis 41:465\u2013471. https:\/\/doi.org\/10.1007\/s10585-024-10291-5","journal-title":"Clin Exp Metastasis"},{"key":"5735_CR69","doi-asserted-by":"publisher","unstructured":"Kim CH, Lee S, Choi JY, Lyu MJ, Jung HM, Goo YT, Kang MJ, Choi YW (2023) Functionalized Lipid nanocarriers for simultaneous delivery of docetaxel and tariquidar to chemoresistant cancer cells. Pharmaceutical 16(3), 349. https:\/\/doi.org\/10.3390\/ph16030349","DOI":"10.3390\/ph16030349"},{"key":"5735_CR70","doi-asserted-by":"publisher","unstructured":"Kim SJ, Puranik N, Yadav D, Jin JO, Lee PCW (2023) Lipid nanocarrier-based drug delivery systems: therapeutic advances in the treatment of lung cancer. Int J Nanomed 18, 2659\u20132676. https:\/\/doi.org\/10.2147\/IJN.S406415","DOI":"10.2147\/IJN.S406415"},{"issue":"4","key":"5735_CR71","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1021\/acsptsci.4c00008","volume":"7","author":"N Kiran","year":"2024","unstructured":"Kiran N, Yashaswini C, Maheshwari R, Bhattacharya S, Prajapati B (2024) Advances in precision medicine approaches for colorectal cancer: from molecular profiling to targeted therapies. ACS Pharmacol Transl Sci 7(4):967\u2013990. https:\/\/doi.org\/10.1021\/acsptsci.4c00008","journal-title":"ACS Pharmacol Transl Sci"},{"key":"5735_CR72","doi-asserted-by":"publisher","first-page":"955","DOI":"10.20892\/j.issn.2095-3941.2021.0032","volume":"18","author":"K Kiyotani","year":"2021","unstructured":"Kiyotani K, Toyoshima Y, Nakamura Y (2021) Personalized immunotherapy in cancer precision medicine. Cancer Biol Med 18:955\u2013965. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2021.0032","journal-title":"Cancer Biol Med"},{"key":"5735_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042345","author":"F Kraus","year":"2024","unstructured":"Kraus F, Sultova E, Heinrich K, Jung A, Westphalen C, Tauber C, Kumbrink J, Rudelius M, Klauschen F, Greif P, K\u00f6nig A, Chelariu-Raicu A, Czogalla B, Burges A, Mahner S, Wuerstlein R, Trillsch F (2024) Genetics and beyond: precision medicine real-world data for patients with cervical, vaginal or vulvar cancer in a tertiary cancer center. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25042345","journal-title":"Int J Mol Sci"},{"key":"5735_CR74","doi-asserted-by":"publisher","unstructured":"Lao Y, Shen D, Zhang W, He R, Jiang M (2022) Immune checkpoint inhibitors in cancer therapy\u2014how to overcome drug resistance? Cancers 14. https:\/\/doi.org\/10.3390\/cancers14153575","DOI":"10.3390\/cancers14153575"},{"key":"5735_CR75","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1080\/07357907.2025.2559088","volume":"43","author":"N Laxane","year":"2025","unstructured":"Laxane N, Yadav K (2025) Recent advances in nanocarrier systems for the co-delivery of siRNA and chemotherapeutic drug for breast cancer therapy. Cancer Investig 43:694\u2013713. https:\/\/doi.org\/10.1080\/07357907.2025.2559088","journal-title":"Cancer Investig"},{"key":"5735_CR76","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s12272-026-01609-w","volume":"49","author":"J Le","year":"2026","unstructured":"Le J, Choi MK, Song IS (2026) Recent paclitaxel formulation strategies: expanding the therapeutic index by addressing biopharmaceutical and toxicity limitations. Arch Pharm Res 49:500\u2013533. https:\/\/doi.org\/10.1007\/s12272-026-01609-w","journal-title":"Arch Pharm Res"},{"key":"5735_CR77","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.ovarian25-ia018","author":"J-M Lee","year":"2025","unstructured":"Lee J-M (2025) Abstract IA018: advancing precision therapy through molecular profiling and targeting DNA replication vulnerabilities in ovarian cancer. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.ovarian25-ia018","journal-title":"Cancer Res"},{"key":"5735_CR78","doi-asserted-by":"publisher","unstructured":"Lei Z, Tian Q, Teng Q, Wurpel J, Zeng L, Pan Y, Chen Z (2023) Understanding and targeting resistance mechanisms in cancer. MedComm 4. https:\/\/doi.org\/10.1002\/mco2.265","DOI":"10.1002\/mco2.265"},{"key":"5735_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202007391","author":"X Li","year":"2021","unstructured":"Li X, Li J, Xu J, Chen K, Zhang Z, Duan J, Luo Q, Du Y, Chen S, Xie Y, Lu W (2021) Nanostructure of functional larotaxel liposomes decorated with guanine-rich quadruplex nucleotide-lipid derivative for treatment of resistant breast cancer. Small. https:\/\/doi.org\/10.1002\/smll.202007391","journal-title":"Small"},{"key":"5735_CR80","doi-asserted-by":"publisher","unstructured":"Li Y, Zhang X, Wang Z, Li B, Zhu H (2023) Modulation of redox homeostasis: a strategy to overcome cancer drug resistance. Front Pharmacol 14, 1156538. https:\/\/doi.org\/10.3389\/fphar.2023.1156538","DOI":"10.3389\/fphar.2023.1156538"},{"key":"5735_CR81","doi-asserted-by":"publisher","unstructured":"Li J, Hu J, Yang Y, Zhang H, Liu Y, Fang Y, Qu L, Lin A, Luo P, Jiang A, Wang L (2025) Drug resistance in cancer: molecular mechanisms and emerging treatment strategies. Mol Biomed 6(1):111. https:\/\/doi.org\/10.1186\/s43556-025-00352-w","DOI":"10.1186\/s43556-025-00352-w"},{"key":"5735_CR82","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.2147\/ijn.s497510","volume":"20","author":"Y Li","year":"2025","unstructured":"Li Y, Sun H, Cao D-C, Guo Y, Wu D, Yang M, Wang H, Shao X, Li Y, Liang Y (2025) Overcoming biological barriers in cancer therapy: cell membrane-based nanocarrier strategies for precision delivery. Int J Nanomedicine 20:3113\u20133145. https:\/\/doi.org\/10.2147\/ijn.s497510","journal-title":"Int J Nanomedicine"},{"key":"5735_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2024.1482637","volume":"12","author":"S Liu","year":"2024","unstructured":"Liu S (2024) Self-assembled lipid-based nanoparticles for chemotherapy against breast cancer. Front Bioeng Biotechnol 12. https:\/\/doi.org\/10.3389\/fbioe.2024.1482637","journal-title":"Front Bioeng Biotechnol"},{"key":"5735_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01856-7","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan X (2024) Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-024-01856-7","journal-title":"Signal Transduct Target Ther"},{"key":"5735_CR85","doi-asserted-by":"publisher","unstructured":"Liu Y, Yang Y, Qi X (2025) Combination therapy for overcoming multidrug resistance in breast cancer through hedgehog signaling pathway regulation. Pharmaceutics 17. https:\/\/doi.org\/10.3390\/pharmaceutics17050572","DOI":"10.3390\/pharmaceutics17050572"},{"key":"5735_CR86","doi-asserted-by":"publisher","unstructured":"Maimaitijiang A, He D, Li D, Li W, Su Z, Fan Z, Li J (2024) Progress in research of nanotherapeutics for overcoming multidrug resistance in cancer. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms25189973","DOI":"10.3390\/ijms25189973"},{"key":"5735_CR87","doi-asserted-by":"publisher","unstructured":"Malka D, Borbath I, Lopes A, Couch D, Jimenez M, Vandamme T, Valle J, Wason J, Ambrose E, Dewever L, de Bruyne I, Edeline J, Bridgewater J (2025) Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10\u2014Precision Medicine). ESMO Open 10. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104540","DOI":"10.1016\/j.esmoop.2025.104540"},{"key":"5735_CR88","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41578-020-00269-6","volume":"6","author":"M Manzari","year":"2021","unstructured":"Manzari M, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller D (2021) Targeted drug delivery strategies for precision medicines. Nat Rev Mater 6:351\u2013370. https:\/\/doi.org\/10.1038\/s41578-020-00269-6","journal-title":"Nat Rev Mater"},{"key":"5735_CR89","doi-asserted-by":"publisher","unstructured":"Marwah H, Dewangan HK (2024) Advancements in solid lipid nanoparticles and nanostructured lipid carriers for breast cancer therapy. Curr Pharm Des 30(37), 2922\u20132936. https:\/\/doi.org\/10.2174\/0113816128319233240725103706","DOI":"10.2174\/0113816128319233240725103706"},{"key":"5735_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16121549","author":"W Meng","year":"2024","unstructured":"Meng W, Huang L, Guo J, Xin Q, Liu J, Hu Y (2024) Innovative nanomedicine delivery: targeting tumor microenvironment to defeat drug resistance. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics16121549","journal-title":"Pharmaceutics"},{"key":"5735_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03558-0","author":"B Mengistu","year":"2024","unstructured":"Mengistu B, Tsegaw T, Demessie Y, Getnet K, Bitew A, Kinde M, Beirhun AM, Mebratu AS, Mekasha YT, Feleke MG, Fenta MD (2024) Comprehensive review of drug resistance in mammalian cancer stem cells: implications for cancer therapy. Cancer Cell Int. https:\/\/doi.org\/10.1186\/s12935-024-03558-0","journal-title":"Cancer Cell Int"},{"key":"5735_CR92","doi-asserted-by":"publisher","unstructured":"Mir S, Hamid L, Bader G, Shoaib A, Rahamathulla M, Alshahrani M, Alam P, Shakeel F (2022). Role of nanotechnology in overcoming the multidrug resistance in cancer therapy: a review. Molecules 27. https:\/\/doi.org\/10.3390\/molecules27196608","DOI":"10.3390\/molecules27196608"},{"key":"5735_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/jmp6030020","author":"G Molla","year":"2025","unstructured":"Molla G, Bitew M (2025) The future of cancer diagnosis and treatment: unlocking the power of biomarkers and personalized molecular-targeted therapies. J Mol Pathol. https:\/\/doi.org\/10.3390\/jmp6030020","journal-title":"J Mol Pathol"},{"key":"5735_CR94","doi-asserted-by":"publisher","unstructured":"Mosele M, Westphalen C, Stenzinger A, Barlesi F, Bayle A, Bi\u00e8che I, Bonastre J, Castro E, Dienstmann R, Kr\u00e4mer A, Czarnecka A, Meric-Bernstam F, Michiels S, Miller R, Normanno N, Reis-Filho J, Remon J, Robson M, Rouleau E, \u2026 Andr\u00e9 F (2024) Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.005","DOI":"10.1016\/j.annonc.2024.04.005"},{"key":"5735_CR95","doi-asserted-by":"publisher","unstructured":"Muhar AM, Velaro A, Prananda A, Nugraha S, Halim P, Syahputra R (2025) Precision medicine in colorectal cancer: genomics profiling and targeted treatment. Front Pharmacol 16. https:\/\/doi.org\/10.3389\/fphar.2025.1532971","DOI":"10.3389\/fphar.2025.1532971"},{"key":"5735_CR96","doi-asserted-by":"publisher","unstructured":"Mukhtar M, El-Readi M, Elzubier M, Fatani S, Refaat B, Shaheen U, Khidir EBA, Taha H, Eid S (2023) Cymbopogon citratus and citral overcome doxorubicin resistance in cancer cells via modulating the drug\u2019s metabolism, toxicity, and multidrug transporters. Molecules 28:3415. https:\/\/doi.org\/10.3390\/molecules28083415","DOI":"10.3390\/molecules28083415"},{"issue":"9","key":"5735_CR97","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41416-018-0235-2","volume":"119","author":"P Munster","year":"2018","unstructured":"Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, Moln\u00e1r I, Wickham TJ, Reynolds J, Campbell K, Hendriks BS, Adiwijaya BS, Geretti E, Moyo V, Miller KD (2018) Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. British journal of cancer 119(9):1086\u20131093. https:\/\/doi.org\/10.1038\/s41416-018-0235-2","journal-title":"British journal of cancer"},{"key":"5735_CR98","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1039\/d5na00323g","volume":"7","author":"NW Nabih","year":"2025","unstructured":"Nabih NW, Hassan H, Preis E, Schaefer J, Babker AM, Abbas A, Amin M, Bakowsky U, Fahmy S (2025) Antibody-functionalized lipid nanocarriers for RNA-based cancer gene therapy: advances and challenges in targeted delivery. Nanoscale Adv 7:5905\u20135931. https:\/\/doi.org\/10.1039\/d5na00323g","journal-title":"Nanoscale Adv"},{"key":"5735_CR99","doi-asserted-by":"publisher","unstructured":"Nag S, Bhunia A, Mohanto S, Ahmed MG, Subramaniyan V (2024) Rising potentials of epigallocatechin gallate (EGCG) loaded lipid-based delivery platforms for breast cancer. Discov Appl Sci 6. https:\/\/doi.org\/10.1007\/s42452-024-05878-2","DOI":"10.1007\/s42452-024-05878-2"},{"key":"5735_CR100","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c01252","author":"A Nel","year":"2022","unstructured":"Nel A, Mei K-C, Liao Y-P, Liu X (2022) Multifunctional lipid bilayer nanocarriers for cancer immunotherapy in heterogeneous tumor microenvironments, combining immunogenic cell death stimuli with immune modulatory drugs. ACS Nano. https:\/\/doi.org\/10.1021\/acsnano.2c01252","journal-title":"ACS Nano"},{"key":"5735_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174363","author":"C Neophytou","year":"2021","unstructured":"Neophytou C, Trougakos I, Erin N, Papageorgis P (2021) Apoptosis deregulation and the development of cancer multi-drug resistance. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13174363","journal-title":"Cancers (Basel)"},{"key":"5735_CR102","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1021\/acsabm.4c01675","volume":"8","author":"CE Okuyucu","year":"2025","unstructured":"Okuyucu CE, Kalaycioglu G, Ozden AK, Aydogan N (2025) Chemosensitizer loaded NIR-responsive nanostructured lipid carriers: a tool for drug-resistant breast cancer synergistic therapy. ACS Appl Bio Mater 8:2167\u20132181. https:\/\/doi.org\/10.1021\/acsabm.4c01675","journal-title":"ACS Appl Bio Mater"},{"key":"5735_CR103","doi-asserted-by":"publisher","unstructured":"Pankiw M, Brezden-Masley C, Charames G (2023) Comprehensive genomic profiling for oncological advancements by precision medicine. Med Oncol 41. https:\/\/doi.org\/10.1007\/s12032-023-02228-x","DOI":"10.1007\/s12032-023-02228-x"},{"key":"5735_CR104","doi-asserted-by":"publisher","unstructured":"Park S, Lu G, Zheng Y, Davison E, Li Y (2025) Nanoparticle-based delivery strategies for combating drug resistance in cancer therapeutics. Cancers 17. https:\/\/doi.org\/10.3390\/cancers17162628","DOI":"10.3390\/cancers17162628"},{"key":"5735_CR105","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","volume":"187","author":"A Passaro","year":"2024","unstructured":"Passaro A, Bakir A, Hamilton E, Diehn M, Andr\u00e9 F, Roy-Chowdhuri S, Mountzios G, Witsuba I, Swanton C, Peters S (2024) Cancer biomarkers - emerging trends and clinical implications for personalized treatment. Cell 187:1617\u20131635. https:\/\/doi.org\/10.1016\/j.cell.2024.02.041","journal-title":"Cell"},{"key":"5735_CR106","doi-asserted-by":"publisher","first-page":"100788","DOI":"10.1016\/j.drup.2021.100788","volume":"60","author":"C Passirani","year":"2021","unstructured":"Passirani C, Vessi\u00e8res A, la Regina G, Link W, Silvestri R (2021) Modulating undruggable targets to overcome cancer therapy resistance. Drug Resistance Updates 60:100788. https:\/\/doi.org\/10.1016\/j.drup.2021.100788","journal-title":"Drug Resistance Updates"},{"key":"5735_CR107","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1515\/mr-2023-0058","volume":"4","author":"H Patel","year":"2024","unstructured":"Patel H, Li J, Bo L, Mehta R, Ashby C, Wang S, Cai W, Chen Z (2024) Nanotechnology-based delivery systems to overcome drug resistance in cancer. Med Rev 4:5\u201330. https:\/\/doi.org\/10.1515\/mr-2023-0058","journal-title":"Med Rev"},{"key":"5735_CR108","doi-asserted-by":"publisher","unstructured":"Pavlinovi\u0107 D\u010c, Pavi\u010di\u0107 J\u0160, Njavro A, Librenjak N, Toma\u0161 I, \u0160eparovi\u0107 R, Ple\u0161tina S, Baji\u0107 \u017d, Plaveti\u0107 D, Vrdoljak E (2025) Precision oncology in clinical practice: two years of comprehensive genomic profiling in Croatia. J Pers Med 15. https:\/\/doi.org\/10.3390\/jpm15020059","DOI":"10.3390\/jpm15020059"},{"key":"5735_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17101315","author":"HK Rachamala","year":"2025","unstructured":"Rachamala HK (2025) Translational advances in lipid nanoparticle drug delivery systems for cancer therapy: current status and future horizons. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics17101315","journal-title":"Pharmaceutics"},{"key":"5735_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26051868","author":"MA Rahman","year":"2025","unstructured":"Rahman MA, Jalouli M, Bhajan S, Al-Zharani M, Harrath A (2025) A comprehensive review of nanoparticle-based drug delivery for modulating PI3K\/AKT\/mTOR-mediated autophagy in cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26051868","journal-title":"Int J Mol Sci"},{"key":"5735_CR111","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/17425247.2022.2044785","volume":"19","author":"S Raikwar","year":"2022","unstructured":"Raikwar S, Jain A, Saraf S, Bidla P, Panda P, Tiwari A, Verma A, Jain S (2022) Opportunities in combinational chemo-immunotherapy for breast cancer using nanotechnology: an emerging landscape. Expert Opin Drug Deliv 19:247\u2013268. https:\/\/doi.org\/10.1080\/17425247.2022.2044785","journal-title":"Expert Opin Drug Deliv"},{"key":"5735_CR112","doi-asserted-by":"publisher","unstructured":"Ramayanam NR, Bukke SPN, Moka MK, Dehingia H, Bordoloi A, Debbarma R, Kudumula PR, Vuyyala B, Prasad P, Catherine A (2025) Advances in nanoparticle-based doxorubicin delivery: precision strategies for targeted treatment of triple-negative breast cancer. Discover Nano 20. https:\/\/doi.org\/10.1186\/s11671-025-04308-5","DOI":"10.1186\/s11671-025-04308-5"},{"key":"5735_CR113","doi-asserted-by":"publisher","unstructured":"Rethi L, Mutalik C, Anurogo D, Lu L-S, Chu H-Y, Yougbar\u00e9 S, Kuo T-R, Cheng T, Chen F (2022) Lipid-based nanomaterials for drug delivery systems in breast cancer therapy. Nanomaterials 12. https:\/\/doi.org\/10.3390\/nano12172948","DOI":"10.3390\/nano12172948"},{"key":"5735_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-02856-6","author":"H Rezayatmand","year":"2022","unstructured":"Rezayatmand H, Razmkhah M, Razeghian-Jahromi I (2022) Drug resistance in cancer therapy: the Pandora\u2019s box of cancer stem cells. Stem Cell Res Ther. https:\/\/doi.org\/10.1186\/s13287-022-02856-6","journal-title":"Stem Cell Res Ther"},{"key":"5735_CR115","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00428-023-03702-7","volume":"484","author":"J Riedl","year":"2023","unstructured":"Riedl J, Moik F, Esterl T, Kostmann S, Gerger A, Jost P (2023) Molecular diagnostics tailoring personalized cancer therapy\u2014an oncologist\u2019s view. Virchows Arch 484:169\u2013179. https:\/\/doi.org\/10.1007\/s00428-023-03702-7","journal-title":"Virchows Arch"},{"key":"5735_CR116","doi-asserted-by":"publisher","unstructured":"Rituraj, Pal RS, Wahlang J, Pal Y, Chaitanya MV, Saxena S. (2025) Precision oncology: transforming cancer care through personalized medicine. Med Oncol 42. https:\/\/doi.org\/10.1007\/s12032-025-02817-y","DOI":"10.1007\/s12032-025-02817-y"},{"key":"5735_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212402","author":"M Roszkowska","year":"2024","unstructured":"Roszkowska M (2024) Multilevel mechanisms of cancer drug resistance. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms252212402","journal-title":"Int J Mol Sci"},{"key":"5735_CR118","doi-asserted-by":"publisher","unstructured":"Sabir S, Thani ASB, Abbas Q (2025). Nanotechnology in cancer treatment: revolutionizing strategies against drug resistance. Front Bioeng Biotechnol 13. https:\/\/doi.org\/10.3389\/fbioe.2025.1548588","DOI":"10.3389\/fbioe.2025.1548588"},{"key":"5735_CR119","doi-asserted-by":"publisher","unstructured":"Sabit H, Pawlik T, Radwan F, Abdel-Hakeem M, Abdel-Ghany S, Wadan AHS, Elzawahri M, El-Hashash A, Arneth B (2025) Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery. Mol Cancer 24. https:\/\/doi.org\/10.1186\/s12943-025-02357-z","DOI":"10.1186\/s12943-025-02357-z"},{"key":"5735_CR120","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1021\/acsomega.3c07432","volume":"9","author":"M Safarkhani","year":"2023","unstructured":"Safarkhani M, Moghaddam SS, Taghavimandi F, Bagherzadeh M, Fatahi Y, Park U, Radmanesh F, Huh Y, Rabiee N (2023) Bioengineered smart nanocarriers for breast cancer treatment: adorned carbon-based nanocomposites with silver and palladium complexes for efficient drug delivery. ACS Omega 9:1183\u20131195. https:\/\/doi.org\/10.1021\/acsomega.3c07432","journal-title":"ACS Omega"},{"key":"5735_CR121","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1515\/nanoph-2021-0142","volume":"10","author":"T Saha","year":"2021","unstructured":"Saha T, Mondal J, Khiste S, Lusic H, Hu Z, Jayabalan R, Hodgetts K, Jang H, Sengupta S, Lee SE, Park Y, Lee L, Goldman A (2021) Nanotherapeutic approaches to overcome distinct drug resistance barriers in models of breast cancer. Nanophotonics 10:3063\u20133073. https:\/\/doi.org\/10.1515\/nanoph-2021-0142","journal-title":"Nanophotonics"},{"key":"5735_CR122","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1080\/03639045.2025.2564364","volume":"51","author":"R Sangavi","year":"2025","unstructured":"Sangavi R, Khute S, Subash P (2025) Advances in novel drug delivery systems: a focus on nanoparticles and mucoadhesive technologies. Drug Dev Ind Pharm 51:1673\u20131688. https:\/\/doi.org\/10.1080\/03639045.2025.2564364","journal-title":"Drug Dev Ind Pharm"},{"key":"5735_CR123","doi-asserted-by":"publisher","unstructured":"Schneider LP, Maselli-Schoueri J, de Souza Gutierres Aguiar B, Aguiar N, del Giglio A (2025) Addressing challenges in the implementation of precision oncology: an in-depth examination of limitations and disparities in the treatment of non-small cell lung cancer in the Brazilian public healthcare system (SUS). Glob Public Health 20. https:\/\/doi.org\/10.1080\/17441692.2025.2450412","DOI":"10.1080\/17441692.2025.2450412"},{"key":"5735_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, Crommelin DJA (2021) mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. International journal of pharmaceutics 601:120586. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120586","journal-title":"International journal of pharmaceutics"},{"key":"5735_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105771","author":"V Segu\u00ed","year":"2025","unstructured":"Segu\u00ed V, Carbonell-Asins J, Mart\u00edn-Arana J, Garc\u00eda-Bartolom\u00e9 M, Grimalt N, Mart\u00ednez-Ciarpaglini C, Gonzalez-Mu\u00f1oz JF, Mart\u00edn-Martorell P, Gonz\u00e1lez-Barrallo I, Viala A, Tapia M, Huerta M, Bruixola G, Insa A, Cejalvo JM, Fleitas T, Tarazona N, Cervantes A, Roda D, Gambardella V (2025) Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105771","journal-title":"ESMO Open"},{"key":"5735_CR126","doi-asserted-by":"publisher","unstructured":"Selvakumar S, Preethi K, Ross K, Tusubira D, Khan M, Mani P, Rao T, Sekar D (2022) CRISPR\/Cas9 and next generation sequencing in the personalized treatment of Cancer. Mol Cancer 21. https:\/\/doi.org\/10.1186\/s12943-022-01565-1","DOI":"10.1186\/s12943-022-01565-1"},{"key":"5735_CR127","doi-asserted-by":"publisher","unstructured":"Sen S, Xavier J, Kumar N, Ahmad MZ, Ranjan OP (2023) Exosomes as natural nanocarrier-based drug delivery system: recent insights and future perspectives. 3 Biotech, 13(3), 101. https:\/\/doi.org\/10.1007\/s13205-023-03521-2","DOI":"10.1007\/s13205-023-03521-2"},{"key":"5735_CR128","doi-asserted-by":"publisher","DOI":"10.1007\/s12609-026-00655-z","volume":"18","author":"A Shadab","year":"2026","unstructured":"Shadab A, Al-Shdefat R (2026) Neurocognitive dysfunction (\u2018ChemoBrain\u2019) in breast cancer survivors: mechanisms and emerging therapeutic strategies. Curr Breast Cancer Rep 18. https:\/\/doi.org\/10.1007\/s12609-026-00655-z","journal-title":"Curr Breast Cancer Rep"},{"issue":"02\/03","key":"5735_CR129","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1055\/a-2795-7008","volume":"76","author":"AA ShadabAbdulFaiz","year":"2026","unstructured":"ShadabAbdulFaiz AA (2026) Translational insights into liposomal drug delivery: recent advances, therapeutic applications, and clinical trials. Drug Research 76(02\/03):65\u201381. https:\/\/doi.org\/10.1055\/a-2795-7008","journal-title":"Drug Research"},{"key":"5735_CR130","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf152","author":"N Shah","year":"2025","unstructured":"Shah N, Meric-Bernstam F (2025) The present and future of precision oncology and tumor-agnostic therapeutic approaches. Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyaf152","journal-title":"Oncologist"},{"key":"5735_CR131","doi-asserted-by":"publisher","unstructured":"Shao F, Li Z, Xiao H, Chen Y, Zhang Y, Li L, Peng Y, Li X, Hou Y, Li B, Chu X, Ran M, Tang D, Han X, Yao J, Zhang C, Wang L, Li H, Shao N, \u2026, Deng CX (2025) Suppressing protein damage response to overcome multidrug resistance in cancer therapy. Cell Discovery 11. https:\/\/doi.org\/10.1038\/s41421-025-00826-9","DOI":"10.1038\/s41421-025-00826-9"},{"key":"5735_CR132","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.7150\/thno.103636","volume":"15","author":"X Shao","year":"2025","unstructured":"Shao X, Zhao X, Wang B, Fan J, Wang J, An H (2025) Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy. Theranostics 15:1689\u20131714. https:\/\/doi.org\/10.7150\/thno.103636","journal-title":"Theranostics"},{"key":"5735_CR133","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.apsb.2022.11.009","volume":"13","author":"S Shen","year":"2022","unstructured":"Shen S, Li T, Fan J, Shao Q, Dong H, Xu X, Mo R (2022) Lipid-polymer hybrid nanoparticle with cell-distinct drug release for treatment of stemness-derived resistant tumor. Acta Pharm Sin B 13:1262\u20131273. https:\/\/doi.org\/10.1016\/j.apsb.2022.11.009","journal-title":"Acta Pharm Sin B"},{"key":"5735_CR134","doi-asserted-by":"publisher","unstructured":"Shi Z, Zeng Y, Luo J, Wang X, Guangrong, Zhang T, Huang P (2024) Endogenous magnetic lipid droplet-mediated cascade-targeted sonodynamic therapy as an approach to reversing breast cancer multidrug resistance. ACS Nano. https:\/\/doi.org\/10.1021\/acsnano.4c05938","DOI":"10.1021\/acsnano.4c05938"},{"key":"5735_CR135","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-01453","author":"J Sicklick","year":"2026","unstructured":"Sicklick J, Nishizaki D, Miyashita H, Okamura R, Hahn M, Nikanjam M, Fanta P, Piccioni D, Patel H, Eskander R, Mckay R, Ross J, Lee J, Lippman S, Kato S, Kurzrock R (2026) Investigation of profile-related evidence determining individualized cancer therapy (I-PREDICT) N-of-1 precision oncology study: molecular profiling to match individually dosed, personalized drug combinations. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco-25-01453","journal-title":"J Clin Oncol"},{"key":"5735_CR136","doi-asserted-by":"publisher","unstructured":"Silverman JA, Deitcher SR (2013) Marqibo\u00ae (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol 71(3):555\u2013564. https:\/\/doi.org\/10.1007\/s00280-012-2042-4","DOI":"10.1007\/s00280-012-2042-4"},{"issue":"1","key":"5735_CR137","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5958\/2321-5836.2020.00002.6","volume":"12","author":"A Singh","year":"2020","unstructured":"Singh A, Ansari VA, Haider F, Akhtar J, Ahsan F (2020) A review on topical preparation of herbal drugs used in liposomal delivery against ageing. Research Journal of Pharmacology and Pharmacodynamics 12(1):5\u201311. https:\/\/doi.org\/10.5958\/2321-5836.2020.00002.6","journal-title":"Research Journal of Pharmacology and Pharmacodynamics"},{"issue":"1","key":"5735_CR138","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5958\/2321-5836.2020.00008.7","volume":"12","author":"A Singh","year":"2020","unstructured":"Singh A, Ansari VA, Haider F, Akhtar J, Ahsan F (2020) Essential oils used in modified drug delivery and its formulation of liposomes for topical purpose. Res J Pharmacol Pharmacodyn 12(1):34\u201338. https:\/\/doi.org\/10.5958\/2321-5836.2020.00008.7","journal-title":"Res J Pharmacol Pharmacodyn"},{"key":"5735_CR139","doi-asserted-by":"publisher","unstructured":"Song J, Yang P, Chen C, Ding WQ, Tillement O, Bai H, Zhang S (2025) Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. Signal Transduct Target Ther 10. https:\/\/doi.org\/10.1038\/s41392-025-02266-z","DOI":"10.1038\/s41392-025-02266-z"},{"key":"5735_CR140","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5483\/bmbrep.2024-0193","volume":"58","author":"Y Song","year":"2025","unstructured":"Song Y, Kong H, Oh S, Kim SB (2025) Plant-derived extracellular vesicles as nanocarriers for combination therapy enhancing paclitaxel-based regimens in breast cancer. BMB Rep 58:53\u201363. https:\/\/doi.org\/10.5483\/bmbrep.2024-0193","journal-title":"BMB Rep"},{"key":"5735_CR141","doi-asserted-by":"publisher","unstructured":"Soragni A, Knudsen E, O\u2019Connor T, Tognon C, Tyner J, Gini B, Kim D, Bivona T, Zang X, Witkiewicz A, Goodrich D, Jiang D, Gammon S, Willey C, Boutros P, Sandulache V, Osman A, Myers J, Mehla K, \u2026 Marathe H (2025) Acquired resistance in cancer: towards targeted therapeutic strategies. Nat Rev Cancer 25:613\u2013633. https:\/\/doi.org\/10.1038\/s41568-025-00824-9","DOI":"10.1038\/s41568-025-00824-9"},{"key":"5735_CR142","doi-asserted-by":"publisher","unstructured":"Stathopoulos GP, Boulikas T (2012) Lipoplatin formulation review article. J Drug Deliv 2012:581363. https:\/\/doi.org\/10.1155\/2012\/581363","DOI":"10.1155\/2012\/581363"},{"issue":"7","key":"5735_CR143","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3390\/ph16070970","volume":"16","author":"MA Subhan","year":"2023","unstructured":"Subhan MA, Filipczak N, Torchilin VP (2023) Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers. Pharmaceuticals (Basel, Switzerland) 16(7):970. https:\/\/doi.org\/10.3390\/ph16070970","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"5735_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01642-x","author":"L Sun","year":"2023","unstructured":"Sun L, Liu H, Ye Y, Lei Y, Islam R, Tan S, Tong R, Miao Y, Cai L (2023) Smart nanoparticles for cancer therapy. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-023-01642-x","journal-title":"Signal Transduct Target Ther"},{"key":"5735_CR145","doi-asserted-by":"publisher","first-page":"390","DOI":"10.20517\/cdr.2023.16","volume":"6","author":"X Sun","year":"2023","unstructured":"Sun X, Zhao P, Lin J, Chen K-M, Shen J (2023) Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system. Cancer Drug Resist 6:390\u2013415. https:\/\/doi.org\/10.20517\/cdr.2023.16","journal-title":"Cancer Drug Resist"},{"key":"5735_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-94393-4","author":"Y Sun","year":"2025","unstructured":"Sun Y, Ren Z, Zhang Z, Yang K, Jin Y, Deng H, Liu Y, Wang J, Ji P, Liu P (2025) Triple synergistic enhancement of breast cancer treatment via chemotherapy, chemodynamic therapy, and tumor starvation therapy driven by lipid-COF nanoparticles. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-025-94393-4","journal-title":"Sci Rep"},{"key":"5735_CR147","doi-asserted-by":"publisher","unstructured":"Szumilak M, Wiktorowska-Owczarek A, Sta\u0144czak A (2021) Hybrid drugs\u2014a strategy for overcoming anticancer drug resistance? Molecules 26. https:\/\/doi.org\/10.3390\/molecules26092601","DOI":"10.3390\/molecules26092601"},{"key":"5735_CR148","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9101353","volume":"9","author":"W Talib","year":"2021","unstructured":"Talib W, Alsayed A, Barakat M, Abu-Taha M, Mahmod A (2021) Targeting drug chemo-resistance in cancer using natural products. Biomedicines 9. https:\/\/doi.org\/10.3390\/biomedicines9101353","journal-title":"Biomedicines"},{"key":"5735_CR149","doi-asserted-by":"publisher","unstructured":"Torres J, Oses JKV, Rabasco-\u00c1lvarez A, Gonz\u00e1lez-Rodr\u00edguez ML, Garc\u00eda M (2025) Innovations in cancer therapy: endogenous stimuli-responsive liposomes as advanced nanocarriers. Pharmaceutics 17. https:\/\/doi.org\/10.3390\/pharmaceutics17020245","DOI":"10.3390\/pharmaceutics17020245"},{"key":"5735_CR150","doi-asserted-by":"publisher","unstructured":"Tsimberidou A, Hong D, Fu S, Karp D, Piha-Paul S, Kies M, Ravi V, Subbiah V, Patel S, Tu S, Janku F, Heymach J, Johnson A, Cartwright C, Zhao L, Zhang J, Berry D, Vining D, Futreal A, \u2026 Meric-Bernstam F (2021) Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. NPJ Precis Oncol 5. https:\/\/doi.org\/10.1038\/s41698-021-00159-2","DOI":"10.1038\/s41698-021-00159-2"},{"key":"5735_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100778","volume":"58","author":"A Valente","year":"2021","unstructured":"Valente A, Podolski-Reni\u0107 A, Poetsch I, Filipovi\u0107 N, L\u00f3pez \u00d3, Turel I, Heffeter P (2021) Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance. Drug Resist Updat 58. https:\/\/doi.org\/10.1016\/j.drup.2021.100778","journal-title":"Drug Resist Updat"},{"key":"5735_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1296091","author":"I Waheed","year":"2024","unstructured":"Waheed I, Ali A, Tabassum H, Khatoon N, Lai WF, Zhou X (2024) Lipid-based nanoparticles as drug delivery carriers for cancer therapy. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2024.1296091","journal-title":"Front Oncol"},{"key":"5735_CR153","doi-asserted-by":"publisher","unstructured":"Wang N, Ting-Xing, Yu T (2023) Targeting epigenetic regulators to overcome drug resistance in cancers. Signal Transduct Target Ther 8. https:\/\/doi.org\/10.1038\/s41392-023-01341-7","DOI":"10.1038\/s41392-023-01341-7"},{"key":"5735_CR154","doi-asserted-by":"publisher","unstructured":"Wang W, Zhou M, Xu Y, Peng W, Zhang S, Li R, Zhang H, Zhang H, Cheng S, Wang Y, Wei X, Yue C, Yang Q, Chen C (2021) Resveratrol-loaded TPGS-resveratrol-solid lipid nanoparticles for multidrug-resistant therapy of breast cancer: in vivo and in vitro study. Front Bioeng Biotechnol 9. https:\/\/doi.org\/10.3389\/fbioe.2021.762489","DOI":"10.3389\/fbioe.2021.762489"},{"key":"5735_CR155","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1080\/10717544.2022.2079771","volume":"29","author":"C Wang","year":"2022","unstructured":"Wang C, Li F, Zhang T, Yu M, Sun Y (2022) Recent advances in anti-multidrug resistance for nano-drug delivery system. Drug Deliv 29:1684\u20131697. https:\/\/doi.org\/10.1080\/10717544.2022.2079771","journal-title":"Drug Deliv"},{"key":"5735_CR156","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, Lin L (2024) Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precision Oncology 8. https:\/\/doi.org\/10.1038\/s41698-024-00522-z","journal-title":"NPJ Precision Oncology"},{"key":"5735_CR157","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1584630","author":"Q Wang","year":"2025","unstructured":"Wang Q, Li K, Li L, Li Q, Qi Y, Liu K, Yuan H, Lin P (2025) The role and therapeutic potential of glucose metabolism in multidrug resistance of cancer. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2025.1584630","journal-title":"Front Cell Dev Biol"},{"key":"5735_CR158","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jncc.2025.03.002","volume":"5","author":"X Wang","year":"2025","unstructured":"Wang X, Zhou Y, Wang Y, Yang J, Li Z, Liu F, Wang A, Gao Z, Wu C, Yin H (2025) Overcoming cancer treatment resistance: unraveling the role of cancer-associated fibroblasts. J Natl Cancer Cent 5:237\u2013251. https:\/\/doi.org\/10.1016\/j.jncc.2025.03.002","journal-title":"J Natl Cancer Cent"},{"key":"5735_CR159","doi-asserted-by":"publisher","first-page":"6334","DOI":"10.7150\/thno.59342","volume":"11","author":"X Wei","year":"2021","unstructured":"Wei X, Song M, Li W, Huang J, Yang G, Wang Y (2021) Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance. Theranostics 11:6334\u20136354. https:\/\/doi.org\/10.7150\/thno.59342","journal-title":"Theranostics"},{"key":"5735_CR160","doi-asserted-by":"publisher","unstructured":"Wolde T, Bhardwaj V, Pandey V (2025) Current bioinformatics tools in precision oncology. MedComm 6. https:\/\/doi.org\/10.1002\/mco2.70243","DOI":"10.1002\/mco2.70243"},{"key":"5735_CR161","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241813972","author":"C-P Wu","year":"2023","unstructured":"Wu C-P, Li Y-C, Murakami M, Hsiao S-H, Lee Y-C, Huang Y-H, Chang Y-T, Hung T, Wu Y-S, Ambudkar S (2023) Furmonertinib, a third-generation EGFR tyrosine kinase inhibitor, overcomes multidrug resistance through inhibiting ABCB1 and ABCG2 in cancer cells. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241813972","journal-title":"Int J Mol Sci"},{"key":"5735_CR162","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17081037","author":"X Wu","year":"2025","unstructured":"Wu X, Shu Y, Zheng Y, Zhang P, Cong H, Zou Y, Cai H, Zha Z (2025) Recent advances in nanomedicine: cutting-edge research on nano-PROTAC delivery systems for cancer therapy. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics17081037","journal-title":"Pharmaceutics"},{"key":"5735_CR163","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1366260","author":"Y Xiang","year":"2024","unstructured":"Xiang Y, Liu X, Wang Y, Zheng D, Meng Q, Jiang L, Yang S, Zhang S, Zhang X, Liu Y, Wang B (2024) Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1366260","journal-title":"Front Immunol"},{"key":"5735_CR164","doi-asserted-by":"publisher","unstructured":"Xiao H, Zheng Y, Lingling Tian L, Sun Q (2021) Clinically-relevant ABC transporter for anti-cancer drug resistance. Front Pharmacol 12. https:\/\/doi.org\/10.3389\/fphar.2021.648407","DOI":"10.3389\/fphar.2021.648407"},{"key":"5735_CR165","doi-asserted-by":"publisher","unstructured":"Yadav P, Ambudkar S, Prasad R (2022) Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer. J Nanobiotechnol 20. https:\/\/doi.org\/10.1186\/s12951-022-01626-z","DOI":"10.1186\/s12951-022-01626-z"},{"key":"5735_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-69229-2","volume":"14","author":"Z Yan","year":"2024","unstructured":"Yan Z, Xiao P, Ji P, Su R, Ren Z, Xu L, Qiu X, Li D (2024) Enhanced breast cancer therapy using multifunctional lipid-coated nanoparticles combining curcumin chemotherapy and nitric oxide gas delivery. Scientific Reports 14. https:\/\/doi.org\/10.1038\/s41598-024-69229-2","journal-title":"Scientific Reports"},{"key":"5735_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01243-0","author":"J Yang","year":"2022","unstructured":"Yang J, Griffin A, Qiang Z, Ren J (2022) Organelle-targeted therapies: a comprehensive review on system design for enabling precision oncology. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-022-01243-0","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"5735_CR168","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.3390\/pharmaceutics14122682","volume":"14","author":"L Yang","year":"2022","unstructured":"Yang L, Gong L, Wang P, Zhao X, Zhao F, Zhang Z, Li Y, Huang W (2022) Recent Advances in Lipid Nanoparticles for Delivery of mRNA. Pharmaceutics 14(12):2682. https:\/\/doi.org\/10.3390\/pharmaceutics14122682","journal-title":"Pharmaceutics"},{"key":"5735_CR169","doi-asserted-by":"publisher","unstructured":"Yao W, Lin Y, Weng Y, Wu Y, Zheng L, Zheng D, Xi Q, Zhao J (2025) Lipid\u2010based nanoparticles in cancer therapy: advances in targeted drug delivery and therapeutic potential for renal cell carcinoma. Adv Sci 12. https:\/\/doi.org\/10.1002\/advs.202507666","DOI":"10.1002\/advs.202507666"},{"key":"5735_CR170","doi-asserted-by":"publisher","unstructured":"Yoo H, Kim Y, Kim J, Cho H, Kim K (2024) Overcoming cancer drug resistance with nanoparticle strategies for key protein inhibition. Mol 29. https:\/\/doi.org\/10.3390\/molecules29173994","DOI":"10.3390\/molecules29173994"},{"key":"5735_CR171","doi-asserted-by":"publisher","unstructured":"Younas A, Wang S, Asad M, al Mamun A, Majeed S, Sharif A, Zhou Q, Liu Y, Geng P, Shao C, Xiao J (2025) Recent advances in cancer nanomedicine: from smart targeting to personalized therapeutics - pioneering a new era in precision oncology. Mater Today Bio. https:\/\/doi.org\/10.1016\/j.mtbio.2025.102660","DOI":"10.1016\/j.mtbio.2025.102660"},{"key":"5735_CR172","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1527600","author":"E Youssef","year":"2025","unstructured":"Youssef E, Fletcher B, Palmer D (2025) Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology. Front Med. https:\/\/doi.org\/10.3389\/fmed.2024.1527600","journal-title":"Front Med"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05735-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05735-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05735-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:14:51Z","timestamp":1785521691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05735-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":172,"alternative-id":["5735"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05735-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that artificial intelligence\u2013based tools were used only for language editing, grammar correction, and improvement of sentence clarity. No AI tool was used for data generation, data analysis, fabrication of results, tables, and figures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}